Amineptine
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Amineptine: From Anxiety Disorder to Agoraphobia
One-Sentence Summary
Amineptine is an antidepressant. Predictions for it come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The TxGNN model predicts it may be useful for agoraphobia, but there are no registered clinical trials and only 1 publication that mentions the drug, a review of antidepressant comparisons that does not study agoraphobia directly. This is a computational prediction without direct supporting studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder (relations recorded in the knowledge graph; the local licence contains no indication text) |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Number of Approvals | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general pharmacology, amineptine is a tricyclic-type antidepressant thought to act mainly through dopamine reuptake inhibition with weaker noradrenergic effects. This description is not confirmed by the data compiled for this report, so mechanistic confidence is limited.
Agoraphobia belongs to the anxiety spectrum, so a plausible indirect link exists. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The one linked publication is a review of reversible MAO-A inhibitors (mainly moclobemide) in depression. It lists amineptine only as one of several comparators and does not address agoraphobia.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7717094 | 1995 | Review | Acta Psychiatr Scand Suppl | Review of reversible MAO-A inhibitors (brofaromine, moclobemide, toloxatone). Moclobemide was compared with several antidepressants, including amineptine, in depression. It does not directly study amineptine in agoraphobia. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 202233 | Survector 100mg Tablet (Serdia Pharmaceuticals India Pvt Ltd) | Strip of 10 tablets | Not stated in the licence record |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications or drug interaction records were available in the data compiled for this report.
Theoretical concerns noted in the analysis of other predicted indications include possible worsening of paranoid or psychotic-spectrum symptoms with dopaminergic stimulation, and a lack of paediatric safety data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no clinical trial or publication directly studies amineptine in agoraphobia, so the evidence level is L5. Mechanism data and safety information are also missing.
To proceed, the following is needed:
- Mechanism of action data for amineptine
- Package insert warnings and contraindications for the marketed product
- A systematic literature search for amineptine in agoraphobia and panic or phobic disorders
- Comparison with established first-line treatments for agoraphobia (such as SSRIs and cognitive behavioural therapy)
- A review of amineptine’s safety history before considering any new-use study
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.